Influence of brachytherapy (192Ir afterloading) on cell-mediated immune reactions in patients with stage I endometrial cancer

Gerstner, G; Kucera, H; Kudlacek, St.; Micksche, M.

doi:10.1016/0090-8258(89)90036-x

Cited by 2 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of a natural killer activity compromise in patients receiving radiotherapy, agree with previous studies (21,22) reporting sustained immunosuppression influence of radiation therapy in cancer patients, which seems to depend on source, dose, and area of irradiation, as well as on the variables reflected by the patients investigated. In particular, our findings showed an associated decrease of T lymphocytes, with particular regard to helper and natural killer cells, which might justify a secondary impairment of natural cytotoxicity in patients who underwent radiation therapy.…”

Section: Discussionsupporting

confidence: 91%

The relationshp of clinical‐pathologic status and adiuvant treatment with natural hller cell activity in stage I and II endometrial carcinoma

Garzetti¹,

Ciavattini²,

Muzzioli³

et al. 1994

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

I(.I(I Oh.v/er Gjwecol Scmd 1994: 73: 652-657. (ij Acta Obstet Gynecol Scand 1994Ohjwriw. The aim of our study was to evaluate the basal immune reactivity in patients with locally advanced endometrial carcinoma, and the immune modulating effect of adjuvant treatment in cancer population randomized to endocrine or radiation therapy. M t r /~r . ; d otitl t w k o d s . Forty-three patients with F I G 0 stage I and II endometrial carcinoma, treated with primary radical surgery, were randomly selected to receive endocrine (medroxyprogesterone acetate 30 mg weekly and Tamoxifen 300 mg weekly, given consecutively) or radiation adjuvant treatment (external beam photon treatment of the whole pelvis, with an average total dose of 3680 cGy rad). The immune assay included the evaluation of natural killer cell activity by target cell retention of the fluorescent dye carboxyfluoresceyn diacetate. using sensitive cell line K 562. The immunological monitoring was performed before surgery, and !hen before, during, and after adjuvant treatment. Nine patients, who refused any adjuvant treatment, were recruited as controls. Kc.trl1r.s. Patients, matched for age and demographic characteristics. with locally advanced endometrial carcinoma had significantly lower mean values of natural killer activity than in henlthy controls: the decrease of natural cytotoxicity was significantly related to the depth of inyometrial invasion. The adjuvant treatment was associated with a significant immune modulation: patients in endocrine therapeutic regimen showed an increase of natural killer activity. while patients in radiation therapy had a reduction; in the control group there was no significant modification of natural cytotoxicity during negative follow up. ~'~i / i r , /~~. s i f~t i . s .

show abstract

Section: Discussionsupporting

confidence: 91%

The relationshp of clinical‐pathologic status and adiuvant treatment with natural hller cell activity in stage I and II endometrial carcinoma

Garzetti¹,

Ciavattini²,

Muzzioli³

et al. 1994

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

Hadley J. Sharp, Elizabeth K. Wansley, Charlie T. Garnett, Mala Chakraborty, Kevin Camphausen, Jeffrey Schlom, James W. Hodge

Sharp

Wansley²,

Garnett³

et al. 2007

Front Biosci

View full text Add to dashboard Cite

Since its discovery more than a hundred years ago, radiation has been used to treat cancer. In recent decades, advances in radiation technology have expanded the role and value of radiation in imaging and treating many forms of cancer. Currently, there is a growing interest in combining radiation with other modalities, such as immunotherapy, to treat a broad range of malignancies. This article reviews the use of standard and novel combinations of radiation therapy and immunotherapy to eradicate tumor cells. The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics for a variety of reasons. First, there is evidence that immunotherapy is most beneficial when employed early in the disease process and in combination with standard therapies. In addition, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. Finally, as monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in cross-priming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses.

show abstract

Influence of brachytherapy (192Ir afterloading) on cell-mediated immune reactions in patients with stage I endometrial cancer

Cited by 2 publications

References 28 publications

The relationshp of clinical‐pathologic status and adiuvant treatment with natural hller cell activity in stage I and II endometrial carcinoma

The relationshp of clinical‐pathologic status and adiuvant treatment with natural hller cell activity in stage I and II endometrial carcinoma

Hadley J. Sharp, Elizabeth K. Wansley, Charlie T. Garnett, Mala Chakraborty, Kevin Camphausen, Jeffrey Schlom, James W. Hodge

Contact Info

Product

Resources

About